Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer by Patel, KM et al.
1Scientific RepoRts | 7: 5554  | DOI:10.1038/s41598-017-05623-3
www.nature.com/scientificreports
Association Of Plasma And 
Urinary Mutant DNA With Clinical 
Outcomes In Muscle Invasive 
Bladder Cancer
K. M. Patel  1,2,3, K. E. van der Vos  4, C. G. Smith1,2, F. Mouliere1,2, D. Tsui1,2, J. Morris1,2, D. 
Chandrananda  1,2, F. Marass  1,2, D. van den Broek5, D. E. Neal1,6, V. J. Gnanapragasam3, T. 
Forshew1,2,7, B. W. van Rhijn8, C. E. Massie  1,2, N. Rosenfeld1,2 & M. S. van der Heijden4,9
Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% 
improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body 
fluid mutant DNA (mutDNA) may allow non-invasive identification of treatment failure. We collected 
248 liquid biopsy samples including plasma, cell pellet (UCP) and supernatant (USN) from spun urine, 
from 17 patients undergoing NAC. We assessed single nucleotide variants and copy number alterations 
in mutDNA using Tagged-Amplicon- and shallow Whole Genome- Sequencing. MutDNA was detected 
in 35.3%, 47.1% and 52.9% of pre-NAC plasma, UCP and USN samples respectively, and urine samples 
contained higher levels of mutDNA (p = <0.001). Longitudinal mutDNA demonstrated tumour 
evolution under the selective pressure of NAC e.g. in one case, urine analysis tracked two distinct clones 
with contrasting treatment sensitivity. Of note, persistence of mutDNA detection during NAC predicted 
disease recurrence (p = 0.003), emphasising its potential as an early biomarker for chemotherapy 
response.
Bladder Cancer (BC) is the most common malignancy of the urinary tract1. Approximately 25% of BC patients 
have Muscle Invasive Bladder Cancer (MIBC) at diagnosis2. The presence of MIBC signifies aggressive disease 
with a significant risk of metastatic progression. Even after definitive treatment (e.g. radical cystectomy – surgical 
removal of the bladder, adjacent organs and their lymphatic drainage) overall survival (OS) is on average 50% 
over 5 yrs3. Meta-analyses show that cisplatin-based neo-adjuvant chemotherapy (NAC) can improve 5-year 
absolute OS by 6%4–6.
Despite maximum treatment with NAC and radical cystectomy, many patients do not respond to NAC7 and 
MIBC patients often recur within 2 years8. Once disease has progressed outside the bladder, OS survival is tra-
ditionally poor. However, a number of new agents, including immunotherapy and targeted therapies, are being 
tested in large clinical trials. There are currently no verified predictive biomarkers of response to cisplatin based 
NAC in MIBC that could be utilised prospectively, though some studies have shown initial promise using gene 
expression9 or gene mutation status10, DNA repair status11 or detecting proteins identified by gene expression 
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analysis12. Furthermore, biomarkers to predict outcome during NAC are lacking and the predictive capacity of 
cystoscopy or radiological examination is limited13. In patients not responding to NAC, definitive treatment could 
be expedited or other systemic treatments investigated in the neo-adjuvant setting. Of note, the recent success of 
immune checkpoint inhibitors14 provides a possible alternative non-cross-resistant systemic treatment for these 
patients and trials with checkpoint inhibitors have recently been initiated in the peri-operative setting.
Circulating tumour DNA (ctDNA) offers a minimally-invasive means to monitor tumour status. The half-life 
of circulating cell-free DNA is reportedly less than 2 hours15–17 and the allele fraction ratio of mutant:wild type 
DNA (AF) has been shown to reflect tumour burden17–19. The translational potential for mutant DNA in body 
fluids (mutDNA, so called as we analysed both cell-free DNA and cellular DNA) could be even greater in blad-
der cancer due to the possibility of monitoring mutDNA in urine20, a peripheral fluid that truly can be collected 
‘non-invasively’. In BC, the close proximity of tumour to the peripheral fluid reservoir might be expected to lead 
to a greater accumulation of tumour derived DNA.
Recent reports have shown that mutDNA is detectable in the plasma and the urine of patients with BC. Using 
the Affymetrix Oncoscan assay, Togneri et al. demonstrated that mutation profiles present in FFPE tumour spec-
imens were mirrored in matched urinary samples from patients with Non-Muscle Invasive Bladder Cancer21. 
Ward et al. used digital PCR (dPCR) and NGS to analyse the somatic mutation status of cell pellets obtained by 
centrifuging urine samples (UCP) in 120 primary bladder cancer patients and 89 patients post transurethral 
resection (TUR), and detected mutant DNA in 70% of cases22. Furthermore, Birkenkamp-Demtröder et al. 
detected mutant DNA in plasma and urine of patients with BC by sequencing tumour specimens to design per-
sonalised droplet dPCR probes for use in peripheral fluids. In 4/6 patients, personalised probes detected plasma 
ctDNA several months before clinical progression23. These studies mostly focus on non-invasive BC, which are 
often driven by different pathways than MIBC24, and none compared plasma, UCP and USN sampling methods.
The application of mutDNA in BC represents an exciting opportunity for clinical impact in MIBC and, despite 
recent efforts, remains relatively unexplored. Here, we aimed to utilise a combination of Tagged-AMplicon 
Sequencing (TAm-Seq) and shallow Whole Genome Sequencing (sWGS) to interrogate the longitudinal dynam-
ics of mutDNA found in peripheral samples from 17 patients with MIBC undergoing NAC. MutDNA presence 
and levels were compared between matching plasma, UCP and USN samples in order to determine the optimum 
sample type for mutDNA analysis. Furthermore, early mutDNA levels (i.e. from samples extracted pre-NAC and 
immediately before the second cycle of NAC) were correlated with response to NAC, as well as recurrence status. 
Finally, longitudinal analysis of all peripheral sample types was employed to track disease progression, and to 
identify tumour dynamics throughout NAC.
Results
Patient recruitment for longitudinal analysis of mutDNA kinetics. Patients attending the 
Netherlands Cancer Institute (NKI) for cisplatin-based NAC were recruited between March 2014 and October 
2015. We analysed 282 samples from 17 patients with MIBC, including 17 tumour tissue samples (16 FFPE TUR 
and 1 cystectomy; TUR tissue from patient 15 was unavailable), 17 white blood cell samples (buffy coat, BUF) 
and 248 body fluid samples (86 plasma, 78 UCP and 84 USN samples), spanning 86 distinct time-points in total. 
TUR samples were requested from referring hospitals whilst peripheral samples were collected at the NKI prior 
to administration of each cycle of NAC (Fig. 1A). Patients were followed up for a median of 742 days (487–952 
days) following initiation of NAC and 588 days (463–851 days) following definitive therapy. Details of the patient 
demographics, tumour characteristics and treatment are outlined in Table 1. DNA extraction failed in 2 samples 
(1 plasma and 1 USN). DNA concentration was measured by a dPCR assay targeting the RPP30 gene using a 97 bp 
amplicon19. Excluding the two failed samples, we obtained a median of 5,296 amplifiable copies/ml (ranging from 
101 to 937,000 amplifiable copies/ml), with the highest extraction yields from UCP, USN, then plasma samples 
(respective medians in amplifiable copies/ml; 61,600, 5,870 and 3,550, Supplementary Figure 3).
We re-sequenced TUR samples to a median depth of 9600X for SNV analysis and a mean of 14.1 million 
sequencing reads per sample for CNA analysis. To detect mutDNA in liquid biopsy samples, we performed 
re-sequencing to a median depth of 7600X for SNV analysis and a mean of 13.6 million reads/sample for CNA 
analysis. We confirmed that there was no sample crossover between different patients by comparing single nucle-
otide polymorphism (SNP) profiles (Supplementary Figure 4).
Detection of DNA alterations in TUR samples from MIBC patients undergoing NAC. We per-
formed TAm-Seq using a bladder-specific sequencing panel (Fig. 2 and methods) on all samples, for the analysis 
of SNVs, as previously described25. The initial panel design included primers targeting the promoter region of 
TERT, but the resulting short amplicons (<120 bp) did not perform well due to the repetitive sequences in this 
region and were excluded from further analysis. We detected a total of 22 SNVs across 12 of the 16 patients 
(Fig. 1C, Supplementary Table 1). The most frequent mutations detected were in TP53 (14 mutations across 10 
patients), followed by KRAS (3 mutations), then PIK3CA (2 mutations). One SNV each was also detected in the 
BRAF, CTNNB1 and FGFR3 genes. These findings agree with previous studies annotating the frequency of SNVs 
in MIBC24, 26. Though the numbers of SNVs detected in TUR samples varied amongst patients, there was no cor-
relation with SNVs in TUR per patient and clinical outcome.
Furthermore, we developed an sWGS approach, adapted from published methods27, to assess CNAs in TUR. 
Gross genome wide CNAs were detected in all tumour specimens, including for those 5 patients in whom no 
SNVs were observed (Fig. 1C). Across the 16 TUR samples, we detected focal CDKN2A loss (37.5%), E2F3/SOX4 
gain (37.5%), PPARG gain (25.0%), YWHAZ gain (18.8%), CREBBP loss (12.5%), MYCL1 gain (12.5%) and CNAs 
of other BC genes, as previously shown24.
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Figure 1. Analysis of Longitudinal mutDNA kinetics in MIBC. (A) Study design. 17 patients were enrolled 
at the NKI for mutDNA analysis whilst undergoing NAC. TUR was performed at the NKI or at regional 
institutions. PLS, UCP and USN were taken on one occasion before the initiation of NAC and subsequently 
on each chemotherapy visit, prior to definitive therapy. (B) Examples of longitudinal SNV and CNA analysis 
performed for each sample are shown. (C) Grid depicting mutDNA detection across all patients and time-
points. The y-axis shows patients grouped by recurrence status, (right-side) and individual mutations (left-
side). The x-axis shows sample-types (top) and time-points (bottom). Each cell of the grid indicates the result 
of a mutation analysis at that time-point (mutant-time-point analysis). White cells correspond to unavailable 
samples and light blue cells to samples where analysis did not detect mutDNA. Purple, yellow, red and green 
cells correspond to TUR, PLS, UCP and USN samples (respectively) where a mutDNA was detected. No 
mutations were detected in BUF (Grey). Raw AFs for the grid are provided in Supplementary Table 4.
Pt 
IDs
Age at 
TUR Sex
No. of Samples Collected
TUR 
Grade
TUR & 
Imaging 
Stage
Post TUR 
Diagnostic 
Cystoscopy
Definitive 
Treatment
Final 
Pathology
Time to 
RecurrenceTUR BUF PLS UCP USN
2 57 M 1 1 4 4 4 3 T3N0M0 3 CR —
7 48 F 1 1 6 5 6 3 T3N0M0 0 RC + LND T0N0
8 76 M 1 1 5 4 5 3 T3N0M0 0 RC + LND T0N0
9 71 F 1 1 5 4 5 3 T3N0M0 2 RC + LND T3N0 378
11 49 F 1 1 5 5 5 3 T2N0M0 2 RC + LND T0 Other*
12 66 M 1 1 4 4 4 3 T2N0M0 2 Rad — 269
13 58 M 1 1 5 5 5 3 T3N0M0 1 RC + LND T2N1 507
15 66 F 0 1 6 5 6 3 T3N1M0 3 RC + LND T3N2 293
18 56 M 1 1 6 6 6 2 T4N0M0 2 RC + LND T3N2
264
19 57 M 1 1 6 5 5 3 T3N0M0 1 RC + LND T0N0
21 64 F 1 1 4 4 4 3 T3N0M0 2 RC + LND T0
466
24 66 M 1 1 5 5 5 3 T3N0M0 1 RC + LND T0 N1
26 50 M 1 1 6 6 6 3 T3N0M0 1 Partial RC + Rad T3
47227 58 M 1 1 4 3 4 3 T3N2M0 2 RC T0
29 59 M 1 1 6 6 6 3 T3N0M0 ND RC + LND T3
32 65 M 1 1 5 3 4 3 T3N0M0 1 RC + LND T3
283
33 70 M 1 1 4 4 4 3 T3N1M0 0 1. CR 2. LND N0
Table 1. Demographics of 17 MIBC patients. The median age at time of TUR was 59 with the cohort consisting 
of 12 males (M) and 5 females (F), in keeping with the prevalence of BC. The number of TUR, BUF, PLS, 
UCP and USN samples obtained for each patient are presented. All patients with MIBC had high-grade (G2-
3), locally advanced disease and opted for Radical Cystectomy (RC). Furthermore, 8/17 patients had early 
recurrence (median 336 days, ranging from 264 to 507). One patient (*) died shortly after surgery due to 
surgical complication and was thus excluded from further analysis involving correlations with early recurrence 
outcome. TUR and imaging stage information and final pathology are provided as per TNM criteria. CR – 
Chemoradiotherapy, Rad – Radiotherapy, LND – Lymph Node Dissection, ND – Not done.
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Comparison of genomic profiles in tumour and pre-NAC peripheral samples and correlation 
with response to NAC. We collected samples immediately prior to starting NAC, 1–2 months after TUR 
(Supplementary Table 1). Of the 12 patients with SNVs detected in TUR, one or more identical SNVs were also 
detected in 30.8% (4/12) 46.2% (5/12) and 46.2% (5/12) of pre-NAC plasma, UCP and USN samples respectively. 
Similarly, CNAs were observed in 25% (4/16), 53.3% (8/15) and 50% (8/16), and of pre-NAC plasma, UCP and 
USN samples of all patients with available samples. When a mutDNA CNA signal was detectable in peripheral 
fluids, the CNA profile subjectively matched the CNA profile of the corresponding TUR. Linear modeling of 
CNA profiles from each peripheral fluid, in which a CNA was called and the matched TUR resulted in a median 
adjusted R2 of 0.4990 (range 0.0011–0.9777) and is likely to represent the reduced prominence of CNA profiles 
in the peripheral samples, possibly due to higher levels of germ-line DNA in urine and plasma samples, due to 
successful removal of the bulk of disease by TUR, or due to spatial and temporal tumour heterogeneity (discussed 
below). When combining both methods, mutations (SNVs and CNAs) were detected in the first (pre-NAC) 
time-point in 58.8% (10/17) patients. MutDNA was present at the pre-NAC time-point in 35.3% (6/17), 47.1% 
(8/17) and 52.9% (9/17) of plasma, UCP and USN samples respectively.
MutDNA was detected in pre-NAC samples in 6 patients who showed complete or partial response and in 4 
patients who showed no response or progression according to final pathology at radical cystectomy. 5 patients 
who responded and 2 patients who did not, showed no evidence of mutDNA at this time-point. Therefore, the 
detection of mutDNA in pre-NAC samples did not correlate with the early response to NAC in this sample set 
(Supplementary Table 2). 16/17 patients had diagnostic flexible cystoscopy following TUR, before NAC was com-
menced. On cystoscopy, 8/16 patients had obvious residual tumour present, and mutDNA was detected in the 
peripheral samples in 6/8 patients with residual tumour and in 1/3 patients with no obvious residual tumour. 
mutDNA was detected in a further 3/5 patients with equivocal cystoscopy findings. There was no correlation with 
patient age, sex or stage and the pathological response to NAC, nor the status of recurrence.
Presence of mutDNA during NAC is associated with recurrence. The majority of mutDNA was 
detected in samples taken from patients who recurred after definitive therapy (Fig. 1C). 8 patients in our cohort 
recurred, with a median time to recurrence of 336 days (maximum 507 days) from initial TUR. One patient 
(patient 11), died due to a post-operative complication of radical cystectomy and was categorised as “other” 
and excluded from further analysis. Patients 8 and 29 developed new primary malignant melanoma and lung 
adenocarcinoma tumours at 882 and 175 days respectively during follow up. These patients were censored at 
the date of new tumour diagnosis to be recurrence free for the purposes of our analysis. Therefore, a total of 8 
patients were recurrence free after a median follow up of 781 days after TUR (maximum 1008 days). Overall, 90 
SNVs were detected in 219 mutant-time-point analyses, and 26 CNAs were detected in 54 samples, from the 8 
patients who recurred (Fig. 1C). However, only 4 SNVs were detected in 193 mutant-time-point analyses and 4 
CNAs were detected in 55 samples tested from the 8 non-recurring patients. Chi-Squared comparison at each 
time-point showed a significantly greater mutDNA detection rate in patients that recurred as compared to those 
that did not at time-points 1, 2, 3 and 5, (p = 0.0058 at T1, p = 0.0055 at T2, p = 0.0130 at T3 and p = 0.0272 at T5 
after Bonferroni correction for multiple testing). Also, SNV AFs at each time-point were significantly higher in 
patients who recurred compared to those who did not (Kolmogorov-Smirnov, p < 0.022 at all time-points after 
correcting for multiple testing, Supplementary Figure 5).
To investigate potential utility of mutDNA analysis for the prediction of recurrence in patients with MIBC, 
we analysed the persistence of mutDNA, in peripheral samples taken at an early on-treatment time-point (i.e. 
just prior to the administration of the 2nd NAC cycle). We utilised TAm-Seq to detect mutDNA at this time-point 
(CNA data were not available) and as such 5 patients were precluded from further analysis as SNVs were not 
detected in their TUR nor peripheral samples. Presence of mutDNA was defined as its detection in one or more 
sample type(s) at an AF, greater than 1/genomic equivalent copies inputted per reaction (our input threshold, raw 
data in Supplementary Table 5) and higher than 0.5% (above our technical threshold). This technical threshold 
was previously described at 2% for the identification, and 0.14% for the detection of SNVs by Forshew et al. in 
201225. Whilst, AUC curves (Supplementary Figure 6) show that a number of thresholds could have been used, we 
utilised a working threshold of 0.5% for our proof of principle study as this ensured 100% specificity, and meant 
Figure 2. Genomic regions interrogated by TAm-Seq for SNV analysis. ^Specificity of TERT assays was poor 
due to constraints of targeting short amplicons in the repetitive TERT promoter region. Data resulting from 
these assays were therefore excluded from downstream analysis. Other than TERT, 90–100% of mutations 
reported in the above listed genes were covered by the panel. Alterations in these genes would capture 72% 
of alterations reported in MIBC patients. The prevalence of the mutations shown here are based upon data 
generated by the TCGA Research Network: http://cancergenome.nih.gov/. Green squares represent missense 
mutations and black squares represent truncating mutations38, 39. The number of patients (and percentage of 
patients) with SNVs detected in TUR and in any body fluid at any time-point are shown for each gene.
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that in buffy coat samples AFs at all genomic co-ordinates with non-reference calls were below our threshold, 
Supplementary Figure 7. Whilst not possible here, future studies could improve on this with more samples and 
employ training and validation sets to determine the optimum threshold.
According to these criteria, mutDNA was present at the 2nd NAC cycle visit in 5 of the 6 patients that recurred, 
whereas it was not detected in any of the cases that did not recur, 83% sensitivity (95% CI: 36–100%) and 100% 
specificity (95% CI: 42–100%), (Fig. 3A and B). All of the patients with detected mutDNA at the 2nd NAC cycle 
had disease recurrence, with a median time to recurrence of 293 days (Fig. 3), whereas patients in whom mutDNA 
was not detected had a low recurrence rate (p = 0.006 using log rank test Fig. 3A resulting in 100% positive pre-
dictive value and 85.7% negative predictive value, Fig. 3B). For the single patient (patient 9) who recurred despite 
not having detectable mutDNA at this time-point in any peripheral sample, the tumour had a PIK3CA E545K 
mutation that was present at an AF of only 0.7%. It is likely that this mutation represents a minor subclone of 
cells in the tumour and therefore may not be present in recurrent tumour. As a biomarker, mutDNA detection in 
samples taken at cycle 2 of NAC offered a median lead-time over radiological detection of recurrence of 243 days 
(range 182–455 days) in our data. This association was primarily driven by detection of TP53 SNVs in the urinary 
samples (Supplementary Figure 8), where 4/5 patients that recurred had mutDNA while only 1/5 patients had a 
BRAF SNV detected in their plasma (Fig. 3C, raw data in Supplementary Table 4).
Comparison of peripheral sample types reveals that UCP and USN are enriched in mutDNA as 
compared to plasma. To identify the most informative peripheral sample type for mutDNA analysis in 
MIBC, we analysed each SNV detected at a single time-point as an independent variable. At 86 time-points all 
3 sample-types were drawn simultaneously, with each of the 31 mutations being detected in at least one of the 
peripheral samples in this group. SNVs were detected most frequently in USN (34.5%, 49/142), UCP (27.5%, 
39/142) and lastly plasma (9.9%, 14/142). Analysing the mutant AFs without imposing detection criteria25, 
AFs were not statistically different between USN and UCP but were higher in UCP and USN when compared 
to plasma (both with p < 0.0001 by Kruskall Wallis and Dunn testing, Fig. 4A and Supplementary Figure 9). 
However, no single peripheral sample type captured all of the SNVs that were detected across all the samples 
together, and for each sample type there were SNVs that were unique to it. Indeed, 4 of the events (individual 
SNVs detected in individual time-points) were detected only in plasma, 2 only in UCP, and 13 only in USN. 
Similarly, CNA analysis was conducted for the first and last time-points, where all three peripheral samples were 
analysed. When CNAs were detected, they were frequently found in all three peripheral sample types. However, 
more CNAs were detected in USN and UCP than plasma but the small numbers precluded statistical interpreta-
tion (Fig. 4B).
We also compared whether SNVs and CNAs co-occurred and whether there was a relationship between them. 
In pre-NAC peripheral samples, though detection rates for SNVs and CNAs were similar, SNVs were not always 
Figure 3. Presence of mutDNA at the 2nd cycle of NAC predicts early recurrence in MIBC. (A) Kaplan-Meier 
curve depicting time to recurrence from initial TUR. We compared the rate of recurrence of patients with 
detectable mutDNA (red line) and undetectable mutDNA (blue line) in peripheral samples taken immediately 
prior to the 2nd cycle of NAC (i.e. 2–3 weeks after the initiation of NAC). MutDNA was detected in 5/6 patients 
who recurred and in 0/6 recurrence free patients. Median time to recurrence in patients with detected mutDNA 
was 293 days while in patients with undetected mutDNA the recurrence rate was low. (B) Sensitivity and 
specificity for recurrence prediction. Overall sensitivity and specificity were 83.3% and 100% with positive 
predict value and negative predictive values of 100% and 85.7% respectively. One “other” patient was excluded 
from recurrence analysis due to post-operative death. (C) Heatmap comparing SNV maximum AF for each 
patient across all sample types and recurrence states at this time-point. Mutant allele fractions (mAFs) are 
represented by coloured cells ranging from white to scarlet as mAF increases (raw data in Supplementary 
Table 4). Patients are grouped by recurrence status. Generally, SNV mAFs are noticeably higher in USN and 
UCP as compared to PLS. There is a clear correlation between SNV mAF in peripheral samples and patient 
recurrence status.
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detected in the same samples as CNAs. Considering all samples, there was generally a greater representation of 
CNAs in samples with higher SNV AFs. However, there were examples of CNA detection where SNV AFs were 
low or were absent altogether (Fig. 1C and Supplementary Figure 10). This was apparent in all peripheral sam-
ple types. This may be due to the ability of sWGS to interrogate a greater breadth of the genome than targeted 
re-sequencing approaches or due to a difference in tumour biology whereby some tumours are CNA driven with 
an absence of SNVs. Our data demonstrates that sampling multiple body fluids using complementary techniques 
allows for more complete assessment of mutDNA.
Longitudinal analysis of mutDNA in peripheral samples of patients with MIBC. We applied 
TAm-Seq to analyse recurrent bladder cancer associated genetic events in serial plasma, UCP and USN peripheral 
samples (taken from NAC initiation through to its completion) to assess trends in mutDNA. Peripheral samples 
were collected longitudinally from each patient over a median of 83 days (46–118 days, median of 15 samples/
patient). CNA analysis was initially applied to the first and final time-points for all patients across all peripheral 
sample types. For both SNV and CNA dynamics, the overall trend was a reduction in mutDNA over time during 
NAC (Figure 4C and Supplementary Figures 11–14). However, there were examples of persisting mutDNA, par-
ticularly in the urinary samples. Furthermore, there were patients who showed variation in mutDNA AFs over 
time.
Urinary mutDNA demonstrates tumour evolution on-therapy. As opposed to assays targeting 
mutations detected in matched tumour samples, combined use of our disease specific assay and sWGS allowed 
the detection of de novo mutations. To determine additional examples of tumour evolution we performed sWGS 
analysis of samples taken between the first and last time-points in selected patients based on high SNV levels or 
interesting CNA profiles at the first time-point (Fig. 1C). In 5 patients there was evidence of dynamic tumour 
evolution during NAC, highlighting the strength of studying mutDNA in peripheral fluids as an alternative to 
Figure 4. Longitudinal analysis of peripheral samples for non-invasive detection of tumour profiles in MIBC. 
(A+B) Venn diagrams demonstrating that more SNVs (A) and CNAs (B) were detected in the urine, as 
compared to the plasma samples. The number of times SNVs or CNAs were detected in peripheral samples per 
time-point (where all three peripheral samples were collected) were depicted as Venn diagrams. 52 out of 56 
SNVs and 12 out of 14 CNAs were detected in urinary samples. However for SNVs, 4 mutations/time-points 
were detected only in PLS, 2 in UCP and 13 in USN. For CNAs 2 mutations/time-points were detected only 
in PLS, 1 in UCP and 3 in USN, confirming that multiple sample analysis can improve mutDNA detection in 
MIBC. (C) Maximum mutDNA AF during NAC demonstrates differing kinetics in PLS, UCP and USN. Three 
plots depict the maximum SNV AF at each time-point in PLS, UCP and USN samples for 13 patients with 
detected SNVs. There are clear differences in the AF kinetics between the peripheral sample types. Generally 
levels are low in PLS while AFs rise and fall dynamically in urinary specimens. For most patients, mAFs are low 
during NAC, however, mAFs that were considerably higher than the 0.005 AF detection threshold were found 
in patients that recurred.
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traditional biopsy approaches25, 28. All de novo mutations were detected in the urinary specimens and were not 
detected in the initial tumour specimen. There was no correlation between the detection of these private muta-
tions and clinical outcome.
In patient 12, whilst mutDNA levels in plasma fell quickly following the initiation of NAC, urinary mutDNA 
levels remained high and reached a peak at 85 days after TUR. Additionally, a new nonsense mutation of TP53 
(W53*) was identified in urinary samples at this time-point (3.6% in UCP and 0.7% in USN), suggesting the 
emergence of a new clone (Supplementary Figure 15a). Similarly overall CNA levels rose in parallel with SNV AFs 
and also demonstrated the emergence of a new CNA profile (including a novel focal amplification of GRIN2A)29, 
30. The short-term persistence of this clone was confirmed by sWGS analysis of additional urine samples from this 
patient (Supplementary Figure 15b). Levels of all mutations ultimately fell, though some were detected at the last 
sample taken during NAC. Although a good response to NAC was initially reported for this patient, he developed 
brain metastases approximately 2 months following radical radiotherapy to the bladder.
Patient 15 had T3N1 disease that recurred 138 days after cystectomy. The SNV and CNA profiles observed 
in her urine specimens suggested tumour evolution in response to surgery and/or NAC. Specifically, a clone 
characterised by a TP53 H193A SNV and a focal amplification of YAP1 was dominant at the pre-NAC time point. 
This sample also carried TP53 R273C and NFE2L2 G31A SNVs but they were detectable at low AFs (Fig. 5A and 
B) and likely represent a minor clone. During NAC, the initially dominant (presumably NAC sensitive) TP53 
H193A, containing clone receded, whilst the minor clone containing TP53 R273C and NFE2L2 G31A SNVs and 
a focal loss of CDKN2A became dominant in all peripheral fluid samples. Radical cystectomy was carried out 155 
days after TUR and 106 days after the initiation of NAC. We obtained DNA from the cystectomy sample and car-
ried out TAm-Seq and sWGS on it. Of note, we found that the clone containing CDKN2A loss and TP53 p.R273C 
and NFE2L2 p.G31A SNVs was present at high levels, whilst there was no evidence of the clone containing YAP1 
gain and the TP53 p.H193A SNV (Fig. 5A and B). The similarity between peripheral samples obtained during 
Figure 5. mutDNA demonstrates on-therapy tumour evolution. (A) SNV plots for patient 15 demonstrate 
tumour evolution. SNV analysis of pre-NAC urinary samples revealed a de novo TP53 H193A mutation (light 
blue), whilst TP53 R273C (purple) and NFE2L2 G31A (orange) SNVs were only observed at low AFs in USN 
samples (1% and 1.1% respectively). During NAC, the clone containing TP53 R273C and NFE2L2 G31A SNVs 
appears to grow considerably, whilst the TP53 H193A SNV containing clone recedes to become undetectable 
at later time-points. This profile was mirrored by the cystectomy sample. (B) CNA profiles demonstrate 
tumour evolution. Marked CNA changes were observed in urine sample at pre-NAC (including YAP1 focal 
amplification). This CNA profile differed from that seen in later time-points. At time-point 6, the CNA profile 
resembles one seen at cystectomy. (C) Concordance of cystectomy and USN CNA profiles during NAC. We 
generated a linear model by fitting autosomal 1 Mb bin read-counts in the cystectomy sample against those 
in peripheral samples. Initial USN CNA profiles are discordant with the cystectomy sample (R2 = 0.0461). 
Subsequently a concordant CNA profile emerges (R2 = 0.8760), mirroring the SNV results. D. Longitudinal 
mutDNA analysis suggests on-therapy tumour evolution. We used the changing SNV and CNA profiles to 
suggest a clonal evolution paradigm in patient 15. (Images adapted from Servier Medical Art).
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NAC and the subsequent cystectomy samples was confirmed by modelling the linear relationship between CNA 
profiles of these samples (Fig. 5C). We also carried out additional sWGS of intermediate time-points for this 
patient and confirmed gradual loss of the pre-NAC CNA profile below our detection threshold. Together this data 
points to ‘on-therapy’ tumour evolution under the selective pressures of NAC, as indicated by apparent changes 
in the dominant clone and its respective AF (Fig. 5D). Whilst most noticeable in USN, this evolution was also 
evident in matched UCP samples, albeit at lower levels. Plasma mutDNA analysis alone would not have demon-
strated evolution in this case, although it did reveal the emergence of the later clone containing CDKN2A loss 
and TP53 p.R273C and NFE2L2 p.G31A SNVs, Supplementary Figure 16. This is possibly due to low mutDNA 
levels at the early time-points, which may in turn be due to spatial differences in the clones resulting in different 
representation of shed DNA in the plasma and urine.
MutDNA analysis can be valuable in multiple disease settings of urothelial cancer. To explore 
the applicability of mutDNA detection in other urothelial cancer settings we used the same methods to analyse 
mutDNA levels in 3 additional patients: patient 1 had ureteric urothelial cell cancer (UCC), patient 10 had met-
astatic BC and patient 30 had renal pelvis UCC (Supplementary Table 3). For patient 1, SNVs in TP53 and KRAS 
that were identified in tumour DNA, were detected at low levels (AFs < 5%) in different peripheral samples at 
different time-points during treatment (Supplementary Figure 17). For patient 10, the CNA profile observed in 
the tumour (including focal loss of CDKN2A and CREBBP) was observed in all peripheral sample types taken 
prior to starting chemotherapy, albeit at lower levels in plasma. MutDNA levels, as inferred by the CNA profile, 
gradually decreased to below the detection threshold of sWGS, first in plasma, and then in UCP and USN during 
treatment (Supplementary Figure 17). For patient 30, the tumour biopsy did not yield sufficient material for DNA 
extraction. Nonetheless we detected SNVs in TP53 and PIK3CA, as well as CNAs (including focal amplifications 
of MYCL1, E2F3/SOX4 and PPARG, and focal loss of CDKN2A) in all peripheral samples. SNVs were detected at 
consistently high AFs in the urinary specimens but at moderate levels in the plasma. Matching CNA profiles were 
seen only in the urinary samples, where they persisted between the two time-points analysed (Supplementary 
Figure 17). These preliminary findings suggest that analysis of mutDNA in body fluids may be useful for disease 
monitoring in multiple urothelial cancer settings.
Discussion
MutDNA analysis has been shown to have translational potential in many solid cancers31. MutDNA has been 
studied in plasma but little data has been presented on the analysis of mutDNA in urine. In our cohort of MIBC 
patients we confirm the presence of SNVs and CNAs previously reported in BC24, 26. We confirm that mutations 
found in TUR samples are detectable in both the plasma and urine of BC patients. Our data, based upon the anal-
ysis of 86 time-points, demonstrate that mutDNA is detected more frequently and at higher levels in urine (both 
USN and UCP) and agrees with previous work23. Importantly however, in some cases mutDNA was only detected 
in one individual sample type. These private mutations could represent local anatomy or biology. For example, 
one could speculate that mutations private to plasma represent tumour clones situated deeper in muscle and/or 
closer to the vasculature. This analysis may be important as such clones could have different clinical outcomes. 
In this study, the observation of such plasma-specific mutations did not associate with response to NAC or early 
recurrence, though the number of patients was small. Nonetheless, our data indicates an advantage in assessing 
both urine (UCP & USN) and plasma for the comprehensive analysis of mutDNA in MIBC. Additionally, the 
observation that urinary AFs were higher than plasma AFs, suggests that the presence of mutDNA in urinary 
samples is due to direct tumour shedding. Beyond BC, this study confirms the role of sampling peripheral fluids 
in close proximity to diseased organs in order to improve the sensitivity of the detection of mutDNA32, 33.
Of potential clinical significance, we found that detection of mutDNA at the second cycle of NAC (2–3 weeks 
after initiation of therapy, depending on the specific regimen) using our methods was indicative of early disease 
recurrence, with a sensitivity of 83% and specificity of 100%. We acknowledge that we have studied a small num-
ber of cases and with a relatively short follow-up period (possibly resulting in recurrence events being missed). 
However, it is noteworthy that MIBC often recurs within 2 years34 and our recurrence rates are comparable with 
published data35. Our proof of principle study therefore encourages further large-scale investigation. In our series, 
the single false negative case was likely due to the narrow focus of our bladder-specific panel, since we only 
detected a PIK3CA mutation in the TUR sample at low AF, which likely represents a minor sub-clone (similar to 
those described in patients 12 and 15). Analysis of additional targets, through the use of an expanded panel for 
targeted sequencing or by capture-based strategies (as has been used in other cancer types)28, 36, may have identi-
fied alternative cancer pathway mutations in this patient. Whilst we attempted to overcome this by interrogating 
the wider cancer genome through CNA profiling24, we note that CNA analysis is limited to detecting mutDNA at 
~5% mutant:wild type AF ratio27. Alternatively, by applying only TP53 detection to the USN of the 9 patients who 
had TP53 mutations in their TUR, a focussed TP53 urinary assay would have detected all 4 patients that recurred 
(Supplementary Figure 8).
If confirmed by larger studies, mutDNA detection in pre-NAC samples and in samples taken before the 
2nd NAC cycle may be used to stratify patients into 3 groups (Fig. 6). Firstly, those that are negative at both 
time-points may have a low (or no) burden of disease after TUR. Secondly, those that have a positive pre-NAC 
sample but negative samples at the 2nd NAC cycle are benefiting from their NAC and subsequent definitive ther-
apy. The final group of patients has detectable mutDNA at both time-points and often progresses. Patients in 
this group are not benefiting from NAC and should be considered for expedited definitive therapy or alterna-
tive systemic therapy (e.g. targeted therapy or immune checkpoint inhibition). The specific mutations arising 
(or persisting) during therapy may inform further therapeutic strategy. Analysis of the presence of mutDNA 
in samples from later time-points was also informative but, would be less clinically useful. An early decision on 
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continuation of NAC would prevent administration of multiple cycles of toxic therapy that is not benefiting the 
patient (Fig. 1C).
We provide the first description of tumour evolution through de novo mutation detection in urinary speci-
mens. We hypothesise that the changes in the mutational profiles observed in these patients represent tumour 
evolution under the selective forces of surgery and NAC. This is exemplified by patient 15. It is likely that multiple 
clones were present initially, with analysis of initial urinary samples highlighting a dominant somatic profile con-
sisting of TP53 H193A and YAP1 gain. Initiation of NAC allowed for the apparent emergence of a distinct (pre-
sumably NAC resistant) tumour clone, containing, TP53 R273C, NFE2L2 G31A and CDKN2A loss. Meanwhile 
the clone containing TP53 H193A and YAP1 gain mutations appears to respond well to NAC and recedes. 
Our data emphasises the presence of multiple concomitant tumour clones and, the importance of monitoring 
mutDNA with an entire sequencing panel (e.g. one targeting all of TP53), rather than relying on the detection of 
known mutations from matched tumour samples. In addition, though we cannot rule out the effects of tumour 
heterogeneity in biasing our radical cystectomy sample analysis, the equivalent longitudinal data from periph-
eral fluid samples suggests that a combined body fluid sampling method is capable of overcoming the effects 
of spatially distinct clones. Overall, our data demonstrates the strength and potential of mutDNA profiling for 
non-invasive monitoring of clonal dynamics throughout therapy.
Our proof of principle study has several weaknesses. Patient numbers were small and thus firm clinical con-
clusions cannot be made. However, by comprehensively studying several biological samples per patient at various 
Figure 6. MutDNA analysis may help stratify patients with MIBC in the future. Based on our data, we have 
generated a model by which a patient’s outcome can be predicted by mutDNA status before and during NAC. 
Specifically, mutDNA status may be used to stratify patients into 3 groups. Firstly, patients with undetectable 
mutDNA pre-NAC and during NAC, have a low (or no) burden of disease (green). Secondly, patients with 
detected mutDNA pre-NAC but with negative samples at the 2nd NAC cycle are likely to benefit from their 
NAC and subsequent definitive therapy (yellow). Finally, patients with mutDNA detected before and during 
NAC are unlikely to benefit from continued NAC and often progress (red). These patients should be considered 
for expedited definitive treatment or alternative treatments (e.g. targeted therapy or immune checkpoint 
inhibition).
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time-points during NAC, we were able to establish a detailed overview of mutDNA in BC and generate specific 
hypotheses that can now be tested in prospective, sufficiently-powered, clinical studies. In addition, although the 
presence of mutDNA at the second cycle of NAC was associated with clinical outcome, we found instances where 
patients with favorable outcome had mutDNA detected in samples at later time-points. At this point, it is unclear 
whether these findings are clinically meaningful. However, it is clear that patients with a favorable outcome tend 
to lose detectable presence of mutDNA (Fig. 1C). Finally, the detection methods chosen have limitations in panel 
size, sequence depth and sensitivity. Although improvement is possible, we believe these represent a reason-
able trade-off in comparison with methods like digital PCR (high coverage but few mutations analysed) and 
capture-based NGS assays (large gene panels but coverage limited by sequencing costs).
Together with previous work, we have demonstrated the utility of urinary mutDNA analysis across the full 
spectrum of bladder cancer. Using multiple sample sources and complementary genetic techniques we have pro-
vided a more rigorous analysis of mutDNA. Furthermore, despite the small numbers of patients, our study high-
lights the important role that mutDNA analysis can have in predicting aggressive disease in MIBC and could offer 
an opportunity for patients to consider expedited definitive therapy or alternative regimens.
Methods
Sample Collection. Approval according to national guidelines was obtained from the NKI Translational 
Research Board (N13KCM/CFMPB250) for the longitudinal analysis of mutDNA in MIBC. All patients 
gave informed consent to participate in this study. All experiments were approved by the Cancer Research 
UK-Cambridge Institute and NKI. Experiments were performed in accordance with relevant guidelines and reg-
ulations. Formalin-fixed paraffin-embedded (FFPE) tumour blocks from the TUR samples were collected from 
referring hospitals. Slides were cut from FFPE blocks and used for Haematoxylin and Eosin (H&E) staining and 
DNA extraction. H&E stains were evaluated to identify areas with >50% tumour cells, from which DNA was 
extracted using the QIAamp DNA mini kit (Qiagen, Germany). Urine and blood samples were collected prior to 
each chemotherapy session and were processed as follows; 10 ml of peripheral blood was drawn into K2-EDTA 
haematology tubes and centrifuged at 380 g for 20 mins. The buffy coat layer was carefully transferred before the 
remaining plasma was aliquoted and spun at 20,000 g for 10 mins. We found that 3 ml urine samples were opti-
mally processed by immediate addition of 0.5 M EDTA with subsequent centrifugation at 380 g for 20 mins and 
aliquoting the urine supernatant, leaving the cell pellet (Supplementary Figure 1). UCP was re-suspended in 1 ml 
of PBS. All peripheral fluids were processed within 6 hours and stored at −80 °C.
Furthermore, we found that DNA extraction from 3 ml of urine supernatant by Circulating Nucleic Acid 
(Qiagen) and Urine DNA Isolation, Slurry Format (Norgen, Canada) kits were equally suitable, Supplementary 
Figure 1. We opted to extract DNA from TUR, BUF, UCP and plasma specimens with QIAamp FFPE Tissue, 
DNeasy, DNA Mini Blood Mini and, Circulating Nucleic Acid (Qiagen) or Qiasymphony respectively. Samples 
were split and DNA extracted by manual and Qiasymphony extraction. Comparison of resulting copies/ml and 
mAFs showed no difference between the two methods (Supplementary Figure 2).
DNA extracted from BUF and UCP samples were subjected to mechanical shearing using either a Covaris 
S220 or LE220 (Covaris, USA). TUR was also sheared using the same protocol due to improved FFPE preserva-
tion methods leading to longer DNA fragment sizes37. Recommended parameters were used to shear fragments 
to an average fragment length of 140–180 bp. Successful shearing was confirmed by running 1 μl of DNA on a 
High-Sensitivity Bioanalyser gel (Agilent, USA).
TAm-Seq. Tagged-AMplicon Sequencing (TAm-Seq) primers were designed to assess the single nucleotide 
variant (SNV) status for hotspots or entire coding regions of 8 genes commonly mutated in bladder cancer, based 
on recent WGS studies24 and the COSMIC database26 (Fig. 2). Genes were incorporated into the panel based on 
the frequency of mutation in WGS studies of BC. Primer details are available on request. DNA input amounts 
for TAm-Seq are provided in Supplementary Table 5. TAm-Seq libraries were prepared as previously described25. 
Libraries were sequenced using an Illumina HiSeq 2500 (Illumina, USA).
sWGS. Libraries were prepared from 10ng of plasma, USN, and sheared TUR, BUF and UCP DNA using 
ThruPLEX Plasma-Seq (Rubicon Genomics, USA). Briefly, end repair and ‘A-tailing’ of fragment ends preceded 
the ligation of truncated Illumina sequencer compatible adapters to fragment ends. Thermocycling of libraries 
completed the adapters through the addition of sample specific index sequences, and was performed as described 
in the Plasma-Seq protocol, using 8 (TUR and BUF) or 8–14 (plasma, UCP and USN) amplification cycles 
depending on subsequent DNA concentration as estimated by inspection of bioanalyser traces. Following ampli-
fication, libraries were cleaned with Agencourt AMPure XP beads (Beckman Coulter, USA) at a 1:1 (v/v) ratio 
and eluted in 30 μl nuclease-free water. Successful library preparation was confirmed using a High-Sensitivity 
Bioanalyser gel and libraries were quantified using SYBR green based qPCR (Kapa Biosystems, USA). Libraries 
were pooled in an equimolar fashion and 125 bp paired end sequencing was performed (to give a mean of 14.2 
million reads per sample) using an Illumina HiSeq 2500 or HiSeq 4000.
Mutation Calling Criteria. TAm-Seq sequencing reads were aligned using BWA and SNVs were detected 
using proprietary SNV calling software, the principles of which were described previously25. All mutation calling 
was performed blinded to the patient outcome. Patient-specific mutation calls were used to determine mutant AFs 
for any time-point from the 13 patients with detected SNVs, with thresholds defined by the highest of mutDNA 
AF > 0.5% (technical threshold, see Results Section) or 1/genomic equivalent copies inputted (sample threshold, 
raw data in Supplementary Table 5). Bases that contained a mutant call at a frequency below this threshold were 
not used for further analysis though AF’s were retained for interpreting longitudinal mutDNA dynamics. NGS 
data were analysed using the R statistical software package40.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 5554  | DOI:10.1038/s41598-017-05623-3
For sWGS analysis, sequence data was analysed using an ‘in-house’ pipeline that briefly consists of the following; 
paired-end sequence reads were aligned to the human reference genome (GRCh37) using BWA (version 0.7.13)41 
after removing any contaminant adapter sequences. SAMtools (version 1.3.1)42 was used to convert files to BAM for-
mat. PCR and optical duplicates were marked using Picard-Tools’ (version 2.2.4) ‘MarkDuplicates’ feature and these 
were excluded from downstream analysis along with reads of low mapping quality and supplementary alignments.
CNA calling was performed in R43 using the QDNAseq pipeline44. Briefly, sequence reads were allocated into 
equally sized (here 1 Mb and 50 kb) non-overlapping bins throughout the length of the genome. Read counts 
in each bin were corrected to account for sequence GC content and mappability, and bins corresponding to 
previously ‘blacklisted’ (ENCODE) and manually blacklisted regions were excluded from downstream analysis. 
Within the QDNAseq package, bins were segmented using the ‘Circular Binary Segmentation’ algorithm45 and 
significantly ‘amplified’ or ‘lost’ regions were called using CGHcall46 – regions were called in peripheral fluids 
independent of the calls from the corresponding TUR sample.
We compared overall levels of copy number imbalance across the length of the genome in our samples by 
calculating a ‘genome-wide imbalance score’. To generate this value, log2 adjusted read counts in a given 1 Mb bin 
were compared against the equivalent value in a control sample. This control sample, which consisted of pooled 
sWGS data from 8 buffy-coat samples, was used for all pairwise comparisons. A linear model was fitted against 
all autosomal bin values of the test sample vs. the control sample and the squared sum of residuals of this fit was 
calculated. To overcome inherent noise surrounding baseline (i.e. copy number neutral) in sWGS data, we only 
considered the sum of the 5% most extreme residual values to represent the ‘genome-wide imbalance score’.
The data that support the findings of this study are available from the corresponding author upon request.
Statistical Inferences. Statistical conclusions were impacted due to the proof of principle nature of the 
study. Where applicable we employed the following statistical analyses: To compare raw AF’s of patients who did 
and did not recur, these two populations were plotted in the form of an empirical cumulative distribution func-
tion and assessed by applying the Kolmogorov–Smirnov test. Analyses of correlation between AFs at the 2nd NAC 
cycle and recurrence was performed using the “OIsurv” package in R47. Survival curves were generated using the 
‘survfit’ function, which uses the Logrank test to compare differences (in the presence of censoring)47. Exact bino-
mial confidence limits for sensitivity and specificity are calculated using the ‘epiR’ package in R48. The SNV AFs 
in different sample types was compared using a Kruskal-Wallis rank sum test after testing for normality. sWGS 
profiles were compared by applying linear-regression modelling to the log ratios of two samples and adjusted R2 
values were generated using the linear model function in R.
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